APx Acquisition Corp. I (APXI) to Combine with OmnigenicsAI, MultiplAI Health in $340M Deal
APx (NASDAQ:APXI) has entered into a definitive agreement to combine with precision medicine firms OmnigenicsAI and MultiplAI at an enterprise value $340 million. Once combined, these companies will offer DNA tests to consumers linked to predictive insights on their nutritional and genomic health. The combined company is expected to trade on the Nasdaq under the
Read More
To access this post, you must purchase 1 - User: Monthly Plan.